Novacyt S.A. (EPA:ALNOV)

Market Cap	31.59M
Revenue (ttm)	22.69M
Net Income (ttm)	-35.47M
Shares Out	70.52M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,550
Average Volume	173,093
Open	0.4500
Previous Close	0.4480
Day's Range	0.4420 - 0.4500
52-Week Range	0.4185 - 0.8400
Beta	1.11
RSI	39.37
Earnings Date	Sep 24, 2025

About Novacyt

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 234
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNOV

Financial Performance

In 2024, Novacyt's revenue was 19.63 million, an increase of 84.82% compared to the previous year's 10.62 million. Losses were -41.76 million, 47.6% more than in 2023.

Financial numbers in GBP